Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design
-
Abstract Number: 2581
Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus
-
Abstract Number: 2582
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2583
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
-
Abstract Number: 2584
Apremilast in Patients with Lupus Rashes
-
Abstract Number: 2585
Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
-
Abstract Number: 2586
Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
-
Abstract Number: 2588
Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
-
Abstract Number: 2589
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
-
Abstract Number: 2590
Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
-
Abstract Number: 2591
Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
-
Abstract Number: 2592
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
-
Abstract Number: 2593
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
-
Abstract Number: 2594
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
-
Abstract Number: 2595
The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
-
Abstract Number: 2596
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
-
Abstract Number: 2597
Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
-
Abstract Number: 2598
The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
-
Abstract Number: 2599
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
-
Abstract Number: 2600
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
-
Abstract Number: 2601
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
-
Abstract Number: 2602
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
-
Abstract Number: 2603
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
-
Abstract Number: 2604
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
-
Abstract Number: 2605
Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
-
Abstract Number: 2606
Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
-
Abstract Number: 2608
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
-
Abstract Number: 2609
A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus
-
Abstract Number: 2610
Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
-
Abstract Number: 2611
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
-
Abstract Number: 2612
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record
-
Abstract Number: 2613
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
-
Abstract Number: 2614
Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
-
Abstract Number: 2615
Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review
-
Abstract Number: 2616
Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
-
Abstract Number: 2617
Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus
-
Abstract Number: 2618
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
-
Abstract Number: 2619
Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
-
Abstract Number: 2620
The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares
-
Abstract Number: 2621
Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution
-
Abstract Number: 2622
The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity
-
Abstract Number: 2623
Association between Smoking Status and the Clinical and Serological Characteristics at the Onset of Systemic Lupus Erythematosus. an Inception Cohort Analysis
-
Abstract Number: 2624
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
-
Abstract Number: 2625
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
-
Abstract Number: 2626
Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes
-
Abstract Number: 2627
Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort
-
Abstract Number: 2628
Raynaud’s Symptoms and Pregnancy Induced Hypertension in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2629
Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
-
Abstract Number: 2630
Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus
-
Abstract Number: 2631
Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE
-
Abstract Number: 2632
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory